ערך בספרים למניה: ChromaDex Corp. (CDXC)

ChromaDex Corporation (CDXC) generates revenue by creating longevity components and collecting royalties for the use of its patents. The change in the book value per share confirms asset dynamics, where 0.60 is recorded as the baseline value. Legal protection of formulas ensures high profitability, while outsourcing chemical synthesis under strict laboratory supervision optimizes the company's operating expenses.

This metric is calculated as the difference between total assets and liabilities divided by the number of shares, reflecting the actual value of the owner's stake excluding market noise. An analysis of the book value per common share allows for an assessment of the capitalization of the Niagen ecosystem and NAD+ scientific developments, while this chart confirms the equity stability of ChromaDex Corporation (CDXC) relative to its debt load.